F C Tenover

Summary

Affiliation: Centers for Disease Control and Prevention
Country: USA

Publications

  1. pmc Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus
    F C Tenover
    Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Emerg Infect Dis 7:327-32. 2001
  2. ncbi request reprint Ability of laboratories to detect emerging antimicrobial resistance in nosocomial pathogens: a survey of project ICARE laboratories
    C D Steward
    Hospital Infections Program, Centers for Disease Control and Prevention, 1600 Clifton Rd, NE G08 Atlanta, GA 30333, USA
    Diagn Microbiol Infect Dis 38:59-67. 2000
  3. pmc Characterization of the extended-spectrum beta-lactamase reference strain, Klebsiella pneumoniae K6 (ATCC 700603), which produces the novel enzyme SHV-18
    J K Rasheed
    Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Antimicrob Agents Chemother 44:2382-8. 2000
  4. pmc Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides
    F C Tenover
    Hospital Infections Program, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Clin Microbiol 36:1020-7. 1998
  5. pmc Detection and differentiation of vanC-1, vanC-2, and vanC-3 glycopeptide resistance genes in enterococci
    N C Clark
    Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Clin Microbiol 36:2294-7. 1998
  6. ncbi request reprint Determinants of vancomycin use in adult intensive care units in 41 United States hospitals
    S K Fridkin
    Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Clin Infect Dis 28:1119-25. 1999
  7. ncbi request reprint Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals
    S K Fridkin
    Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Clin Infect Dis 29:245-52. 1999
  8. pmc Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae
    L M Weigel
    Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Antimicrob Agents Chemother 45:3517-23. 2001
  9. pmc Evolution of extended-spectrum beta-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia
    J K Rasheed
    Nosocomial Pathogens Laboratory Branch, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Antimicrob Agents Chemother 41:647-53. 1997
  10. ncbi request reprint The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units
    S K Fridkin
    Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control and Prevention, MS A 35, 1600 Clifton Road, Atlanta, GA 30333, USA
    Ann Intern Med 135:175-83. 2001

Detail Information

Publications32

  1. pmc Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus
    F C Tenover
    Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Emerg Infect Dis 7:327-32. 2001
    ..The Centers for Disease Control and Prevention and other groups have issued recommendations regarding appropriate infection control procedures for patients infected with these strains...
  2. ncbi request reprint Ability of laboratories to detect emerging antimicrobial resistance in nosocomial pathogens: a survey of project ICARE laboratories
    C D Steward
    Hospital Infections Program, Centers for Disease Control and Prevention, 1600 Clifton Rd, NE G08 Atlanta, GA 30333, USA
    Diagn Microbiol Infect Dis 38:59-67. 2000
    ..This highlights the need for monitoring how well susceptibility test systems in clinical laboratories detect emerging resistance...
  3. pmc Characterization of the extended-spectrum beta-lactamase reference strain, Klebsiella pneumoniae K6 (ATCC 700603), which produces the novel enzyme SHV-18
    J K Rasheed
    Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Antimicrob Agents Chemother 44:2382-8. 2000
    ..In addition to the production of this novel ESBL, designated SHV-18, analysis of the outer membrane proteins of K6 revealed the loss of the OmpK35 and OmpK37 porins...
  4. pmc Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides
    F C Tenover
    Hospital Infections Program, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Clin Microbiol 36:1020-7. 1998
    ..Furthermore, it appears that commercial vancomycin agar screening plates can be used to detect these isolates...
  5. pmc Detection and differentiation of vanC-1, vanC-2, and vanC-3 glycopeptide resistance genes in enterococci
    N C Clark
    Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Clin Microbiol 36:2294-7. 1998
    ..Antimicrobial susceptibility tests and analysis of genomic DNA by pulsed-field gel electrophoresis were also performed, but the results indicated that they were not able to distinguish among strains possessing the three vanC genotypes...
  6. ncbi request reprint Determinants of vancomycin use in adult intensive care units in 41 United States hospitals
    S K Fridkin
    Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Clin Infect Dis 28:1119-25. 1999
    ..Efforts to reduce these rates through infection control activities should be included in hospitals' efforts to reduce vancomycin use...
  7. ncbi request reprint Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals
    S K Fridkin
    Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Clin Infect Dis 29:245-52. 1999
    ..These comparative data on use and resistance among similar areas (i.e., ICU or other inpatient areas) can be used as a benchmark by participating hospitals to focus their efforts at addressing antimicrobial resistance...
  8. pmc Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae
    L M Weigel
    Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Antimicrob Agents Chemother 45:3517-23. 2001
    ..These data suggest that the heterogeneity of mutations will likely increase as pneumococci are exposed to novel fluoroquinolone structures, complicating the prediction of cross-resistance within this class of antimicrobial agents...
  9. pmc Evolution of extended-spectrum beta-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia
    J K Rasheed
    Nosocomial Pathogens Laboratory Branch, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Antimicrob Agents Chemother 41:647-53. 1997
    ..This collection of blood isolates from the same patient appears to represent the in vivo evolution of resistance under selective pressure of treatment with various cephalosporins...
  10. ncbi request reprint The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units
    S K Fridkin
    Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control and Prevention, MS A 35, 1600 Clifton Road, Atlanta, GA 30333, USA
    Ann Intern Med 135:175-83. 2001
    ..Identifying modifiable institutional factors can advance quality-improvement efforts to minimize hospital-acquired infections with VRE...
  11. pmc Optimal inoculation methods and quality control for the NCCLS oxacillin agar screen test for detection of oxacillin resistance in Staphylococcus aureus
    J M Swenson
    Nosocomial Pathogens Laboratory Branch, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Clin Microbiol 39:3781-4. 2001
    ..However, lack of specificity with commercial lots may be difficult to detect using any of the current quality control organisms...
  12. pmc Detection and reporting of organisms producing extended-spectrum beta-lactamases: survey of laboratories in Connecticut
    F C Tenover
    Hospital Infections Program, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Clin Microbiol 37:4065-70. 1999
    ..This survey suggests that many laboratories have difficulty detecting resistance in ESBL and AmpC-producing organisms and may be unaware of the NCCLS guidelines on modifying susceptibility testing reports for ESBL-producing strains...
  13. ncbi request reprint Antimicrobial resistance prevalence rates in hospital antibiograms reflect prevalence rates among pathogens associated with hospital-acquired infections
    S K Fridkin
    Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Clin Infect Dis 33:324-30. 2001
    ..Hospital antibiograms may underestimate the relative frequency of methicillin resistance among Staphylococcus species when associated with hospital-acquired infections...
  14. pmc gyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae
    L M Weigel
    Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Antimicrob Agents Chemother 42:2661-7. 1998
    ..The type and position of amino acid alterations also differed among these six genera. High-level FQ-R frequently was associated with single gyrA mutations in all species of Enterobacteriaceae in this study except E. coli...
  15. pmc Vancomycin-intermediate Staphylococcus aureus in a home health-care patient
    J C Hageman
    Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Emerg Infect Dis 7:1023-5. 2001
    ..The patient was treated successfully with antimicrobial therapy, biliary drainage, and reconstruction. Standard precautions in the home health setting appear successful in preventing transmission...
  16. pmc Characterization of clinical isolates of Klebsiella pneumoniae from 19 laboratories using the National Committee for Clinical Laboratory Standards extended-spectrum beta-lactamase detection methods
    C D Steward
    Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Clin Microbiol 39:2864-72. 2001
    ..The remaining 11.5% of the isolates studied contained beta-lactamases that did not demonstrate a CA effect. An algorithm based on phenotypic analyses is suggested for evaluation of such isolates...
  17. pmc Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae
    H Yigit
    Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Antimicrob Agents Chemother 45:1151-61. 2001
    ..pneumoniae strain 1534 is mainly due to production of a novel Bush group 2f, class A, carbapenem-hydrolyzing beta-lactamase, KPC-1, although alterations in porin expression may also play a role...
  18. pmc A 5' nuclease PCR (TaqMan) high-throughput assay for detection of the mecA gene in staphylococci
    G E Killgore
    Hospital Infections Program, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Clin Microbiol 38:2516-9. 2000
    ..Thus, final results were obtained 2 h after PCR was initiated, as opposed to a requirement of 2 days to examine 96 samples by agarose gel electrophoresis...
  19. ncbi request reprint Validation of Vitek version 7.01 software for testing staphylococci against vancomycin
    P M Raney
    Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    Diagn Microbiol Infect Dis 43:135-40. 2002
    ..01 software, when compared to earlier software versions, laboratories may notice an overall shift in MIC data toward higher vancomycin MICs, although for the most part, this does not affect the categorical interpretations of the results...
  20. ncbi request reprint Vancomycin-resistant enterococci colonization in patients at seven hemodialysis centers
    J I Tokars
    Hospital Infections Program, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Kidney Int 60:1511-6. 2001
    ..We studied the prevalence of and risk factors for VRE at seven outpatient hemodialysis centers (three in Baltimore, MD, USA, and four in Richmond, VA, USA)...
  21. ncbi request reprint Use of pyrosequencing to identify point mutations in domain V of 23S rRNA genes of linezolid-resistant Staphylococcus aureus and Staphylococcus epidermidis
    W Zhu
    Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, 1600 Clifton Road, MS G08, Atlanta, GA 30333, USA
    Eur J Clin Microbiol Infect Dis 26:161-5. 2007
    ..epidermidis that were associated with linezolid resistance. A C2534T mutation was identified in S. epidermidis that was not previously reported in a linezolid-resistant isolate...
  22. pmc Ability of laboratories to detect emerging antimicrobial resistance: proficiency testing and quality control results from the World Health Organization's external quality assurance system for antimicrobial susceptibility testing
    F C Tenover
    Hospital Infections Program, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Clin Microbiol 39:241-50. 2001
    ....
  23. pmc Isolation of Enterobacter intermedium from the gallbladder of a patient with cholecystitis
    C M O'Hara
    Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    J Clin Microbiol 36:3055-6. 1998
    ..The organism is susceptible to the aminoglycosides and imipenem but resistant to the cephalosporins and ciprofloxacin...
  24. pmc Detection of a streptomycin/spectinomycin adenylyltransferase gene (aadA) in Enterococcus faecalis
    N C Clark
    Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Antimicrob Agents Chemother 43:157-60. 1999
    ..Vapnek, Plasmid 13:17-30, 1985). Previous reports of the presence of the aadA gene in enterococci appear to be erroneous and probably describe an aadE gene, since the isolates were reported to be susceptible to spectinomycin...
  25. pmc Comparison of agar dilution, disk diffusion, MicroScan, and Vitek antimicrobial susceptibility testing methods to broth microdilution for detection of fluoroquinolone-resistant isolates of the family Enterobacteriaceae
    C D Steward
    Hospital Infections Program, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Clin Microbiol 37:544-7. 1999
    ..However, the high number of minor errors by all test systems remains a concern...
  26. pmc Vancomycin-resistant enterococci outside the health-care setting: prevalence, sources, and public health implications
    L C McDonald
    Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Emerg Infect Dis 3:311-7. 1997
    ..If transmission with VRE from unrecognized community sources can be identified and controlled, increased incidence of colonization and infection among hospitalized patients may be prevented...
  27. ncbi request reprint Implications of vancomycin-resistant Staphylococcus aureus
    F C Tenover
    Hospital Infections Program, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Hosp Infect 43:S3-7. 1999
    ..Finally, the isolation of such strains in three geographically distinct regions suggests that this phenomenon will continue to occur worldwide...
  28. pmc Assignment of CDC weak oxidizer group 2 (WO-2) to the genus Pandoraea and characterization of three new Pandoraea genomospecies
    M I Daneshvar
    Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, PHS, U S DHHS, Atlanta, GA 30333, USA
    J Clin Microbiol 39:1819-26. 2001
    ..This study also shows that Pandoraea isolates may be encountered in blood cultures from patients without cystic fibrosis...
  29. ncbi request reprint Development and spread of bacterial resistance to antimicrobial agents: an overview
    F C Tenover
    Nosocomial Pathogens Laboratory Branch, Hospital Infections Program, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Clin Infect Dis 33:S108-15. 2001
    ..Judicious use is imperative if we are to preserve our arsenal of antimicrobial agents into the next decade...
  30. pmc Performance of eight methods, including two new rapid methods, for detection of oxacillin resistance in a challenge set of Staphylococcus aureus organisms
    J M Swenson
    Epidemiology and Laboratory Branch, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Clin Microbiol 39:3785-8. 2001
    ..The MRSA-Screen sensitivity improved to 100% if agglutination reactions were read at 15 min. Repeat testing improved the performance of some but not all of the systems...
  31. pmc DNA gyrase and topoisomerase IV mutations associated with fluoroquinolone resistance in Proteus mirabilis
    L M Weigel
    Division of Healthcare Quality Promotion, Anti infectives Section G 08, National Center for Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30333, USA
    Antimicrob Agents Chemother 46:2582-7. 2002
    ..Unlike any other bacterial species analyzed to date, mutation of gyrB appears to be a frequent event in the acquisition of fluoroquinolone resistance among clinical isolates of P. mirabilis...
  32. ncbi request reprint Epidemic Shigella dysenteriae type 1 in Burundi: panresistance and implications for prevention
    A A Ries
    Foodborne and Diarrheal Diseases Branches, Centers for Disease Control and Prevention, Atlanta, Georgia
    J Infect Dis 169:1035-41. 1994
    ..dysenteriae type 1, clinical and epidemiologic features may predict such infection, and efforts to control this epidemic must focus on preventing transmission...